^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

vevoctadekin (ST-067)

i
Other names: ST-067, engineered variant of human interleukin-18, human variant of DR-18, human variant of decoy-resistant IL-18, ST067, ST 067
Associations
Company:
Simcha Therap
Drug class:
IL-18 stimulant
Associations
7d
KEYNOTE-E64: Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 (clinicaltrials.gov)
P1/2, N=316, Recruiting, Simcha IL-18, Inc. | Active, not recruiting --> Recruiting | Trial completion date: Jan 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Jun 2025
Enrollment open • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
TMB-H • MSI-H/dMMR • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • Gazyva (obinutuzumab) • vevoctadekin (ST-067)
2ms
New P1 trial
|
Tecvayli (teclistamab-cqyv) • vevoctadekin (ST-067)
3ms
Enrollment open
|
vevoctadekin (ST-067)
4ms
KEYNOTE-E64: Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 (clinicaltrials.gov)
P1/2, N=316, Active, not recruiting, Simcha IL-18, Inc. | Recruiting --> Active, not recruiting | Phase classification: P1a --> P1/2 | Trial primary completion date: Jun 2024 --> Sep 2024
Enrollment closed • Phase classification • Trial primary completion date • Combination therapy • Metastases
|
ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
Keytruda (pembrolizumab) • Gazyva (obinutuzumab) • vevoctadekin (ST-067)
1year
Clinical • P1/2 data • PD(L)-1 Biomarker • IO biomarker • Metastases
|
IL18 (Interleukin 18)
|
Keytruda (pembrolizumab) • vevoctadekin (ST-067)
over1year
Enrollment change • Combination therapy • Metastases
|
ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
TMB-H • MSI-H/dMMR • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • Gazyva (obinutuzumab) • vevoctadekin (ST-067)
over1year
Phase 1a and Phase 2 Study for PK, PD, Safety and Preliminary Efficacy of ST-067 (clinicaltrials.gov)
P1a, N=198, Recruiting, Simcha IL-18, Inc. | Trial completion date: Jul 2023 --> Jan 2025 | Trial primary completion date: May 2023 --> Jun 2024
Trial completion date • Trial primary completion date
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
TMB-H • MSI-H/dMMR
|
vevoctadekin (ST-067)
over3years
Phase 1a and Phase 2 Study for PK, PD, Safety and Preliminary Efficacy of ST-067 (clinicaltrials.gov)
P1a, N=198, Recruiting, Simcha IL-18, Inc. | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
TMB-H • MSI-H/dMMR
|
vevoctadekin (ST-067)
over3years
Clinical • New P1 trial
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
TMB-H • MSI-H/dMMR
|
vevoctadekin (ST-067)